Auditing Protein Therapeutics Management by Professional APCs: Toward Prevention of Immune Responses against Therapeutic Proteins

  • Dasgupta S
  • Bayry J
  • André S
  • et al.
13Citations
Citations of this article
45Readers
Mendeley users who have this article in their library.

Abstract

Alloimmunization is a crippling concern in the management of patients undergoing administration of protein therapeutics as evidenced in replacement therapy and other treatment procedures. Several issues in the genesis and modulation of such deleterious immune responses have been studied. While authors have focused on the downstream events of the specific immune response and suggested modification of protein therapeutics to eliminate epitopes that interact with B cell receptors, T cell receptors, or MHCII molecules, the mechanisms underlying Ag interaction with APCs, a step upstream of immune effectors, have been grossly neglected. We wish to emphasize that the recent knowledge in understanding the capacities of an APC to handle an Ag and the importance of the surrounding microenvironment in this process are crucial for designing novel protein therapeutics with reduced immunogenicity.

Cite

CITATION STYLE

APA

Dasgupta, S., Bayry, J., André, S., Dimitrov, J. D., Kaveri, S. V., & Lacroix-Desmazes, S. (2008). Auditing Protein Therapeutics Management by Professional APCs: Toward Prevention of Immune Responses against Therapeutic Proteins. The Journal of Immunology, 181(3), 1609–1615. https://doi.org/10.4049/jimmunol.181.3.1609

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free